Idarucizumab in Dabigatran-Treated Patients With Acute Stroke: A Review and Clinical Update [PDF]
Frontiers in NeurologyIdarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in need
Pawel Kermer, Senta Frol, George Ntaios
exaly +5 more sources
Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report [PDF]
HeliyonThis case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced ...
Elia Morando +6 more
doaj +3 more sources
Use of idarucizumab for emergency surgery in patients taking dabigatran [PDF]
Атеротромбоз, 2022 This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova +5 more
doaj +3 more sources
Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
Case Reports in Neurology, 2016 Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of ...
Valentin Held +3 more
doaj +2 more sources
Cardiology and Therapy, 2020 Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016.
Daisuke Nakayama, Masahiro Yasaka
exaly +2 more sources
Кардиоваскулярная терапия и профилактика, 2023 The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy.
G. R. Ramazanov +6 more
doaj +2 more sources
Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]
Scientific ReportsDabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim +4 more
doaj +2 more sources
Idarucizumab for a traumatic head injury patient taking dabigatran
International Journal of Emergency Medicine, 2018 Background Dabigatran is one of the four drugs currently used as a direct oral anticoagulant in Japan. Idarucizumab, which specifically targets dabigatran, was recently approved in Japan.
Shuhei Maruyama +7 more
doaj +2 more sources
Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study [PDF]
Frontiers in Neurology, 2023 BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ...
Nils Kuklik +10 more
doaj +2 more sources
Evidence supporting idarucizumab for the reversal of dabigatran [PDF]
The American Journal of Emergency Medicine, 2016 Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers.
Pollack, Charles V.
core +7 more sources